155 related articles for article (PubMed ID: 2149505)
1. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion.
Schuurmans AL; Bolt J; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):849-53. PubMed ID: 2149505
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Warriar N; Pagé N; Koutsilieris M; Govindan MV
Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
[TBL] [Abstract][Full Text] [Related]
3. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
Berns EM; de Boer W; Mulder E
Prostate; 1986; 9(3):247-59. PubMed ID: 2946029
[TBL] [Abstract][Full Text] [Related]
4. Control of the proliferation of prostate cancer cells by an androgen and two antiandrogens. Cell specific sets of responses.
Foury O; Nicolas B; Joly-Pharaboz MO; André J
J Steroid Biochem Mol Biol; 1998 Aug; 66(4):235-40. PubMed ID: 9744520
[TBL] [Abstract][Full Text] [Related]
5. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens.
Wilding G; Chen M; Gelmann EP
Prostate; 1989; 14(2):103-15. PubMed ID: 2710689
[TBL] [Abstract][Full Text] [Related]
6. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
Veldscholte J; Berrevoets CA; Ris-Stalpers C; Kuiper GG; Jenster G; Trapman J; Brinkmann AO; Mulder E
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):665-9. PubMed ID: 1562539
[TBL] [Abstract][Full Text] [Related]
7. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP.
Schuurmans AL; Bolt J; Mulder E
Prostate; 1988; 12(1):55-63. PubMed ID: 3258066
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of androgen binding in human foreskin fibroblasts by antiandrogens.
Brown TR; Rothwell SW; Sultan C; Migeon CJ
Steroids; 1981 Jun; 37(6):635-48. PubMed ID: 6457421
[TBL] [Abstract][Full Text] [Related]
9. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
10. The kinetics of antiandrogens in humans.
Tremblay D; Dupront A; Meyer BH; Pottier J
Prog Clin Biol Res; 1987; 243A():341-50. PubMed ID: 2958859
[No Abstract] [Full Text] [Related]
11. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones.
Schuurmans AL; Bolt J; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1991; 40(1-3):193-7. PubMed ID: 1958520
[TBL] [Abstract][Full Text] [Related]
12. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
de Voogt HJ
Prostate Suppl; 1992; 4():91-5. PubMed ID: 1533452
[TBL] [Abstract][Full Text] [Related]
13. Effects of castration and antiandrogens (RU 23908 and cyproterone acetate) on glandulain activity and on the secretory epithelium of the rat submandibular gland.
Porto CS; Picarelli ZP; Hayashi H; Abreu LC
Braz J Med Biol Res; 1988; 21(3):591-8. PubMed ID: 2976284
[TBL] [Abstract][Full Text] [Related]
14. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
Rennie PS; Bruchovsky N; Goldenberg SL; Lawson D; Fletcher T; Foekens JA
J Urol; 1988 Jun; 139(6):1337-42. PubMed ID: 2967378
[TBL] [Abstract][Full Text] [Related]
15. The synthetic androgen mibolerone induces transient suppression of the transformed phenotype in an androgen responsive human prostatic carcinoma cell line.
Schulz P; Wolf D; Arbusow V; Bojar H; Klobeck HG; Fittler F
Andrologia; 1990; 22 Suppl 1():56-66. PubMed ID: 2151880
[TBL] [Abstract][Full Text] [Related]
16. Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells.
Hackenberg R; Hofmann J; Hölzel F; Schulz KD
J Cancer Res Clin Oncol; 1988; 114(6):593-601. PubMed ID: 2974456
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
18. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens.
Kuil CW; Mulder E
Endocrinology; 1996 May; 137(5):1870-7. PubMed ID: 8612526
[TBL] [Abstract][Full Text] [Related]
19. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
Steinsapir J; Mora G; Muldoon TG
Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation of prostate kallikrein-like genes by androgen.
Wolf DA; Schulz P; Fittler F
Mol Endocrinol; 1992 May; 6(5):753-62. PubMed ID: 1376410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
